Recent News

• 04.23.2025 - Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
• 03.12.2025 - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
• 03.11.2025 - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
• 02.19.2025 - Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
• 01.28.2025 - Ellie Merle
• 01.28.2025 - Jay Olson, CFA

Recent Filings

• 03.12.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 8-K Current report
• 03.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report
• 02.14.2025 - EX-99.1 EX-99.1
• 02.14.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors